Home
/
Arbutus Biopharma Corp
/
Financials
/
Quarterly
Arbutus Biopharma Corp — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Arbutus Biopharma Corp filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$529.0K
Nov 13, 2025
Q2
2025
Jun 30, 2025
$10.74M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$1.76M
May 14, 2025
Q3
2025
Sep 30, 2024
$1.34M
Nov 13, 2025
Q2
2025
Jun 30, 2024
$1.73M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$1.53M
May 14, 2025
Q3
2024
Sep 30, 2023
$4.66M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$4.65M
Aug 8, 2024
Q1
2024
Mar 31, 2023
$6.69M
May 2, 2024
Q3
2023
Sep 30, 2022
$5.95M
Nov 7, 2023
Q2
2023
Jun 30, 2022
$14.24M
Aug 3, 2023
Q1
2023
Mar 31, 2022
$12.58M
May 4, 2023
Q3
2022
Sep 30, 2021
$3.34M
Nov 9, 2022
Q2
2022
Jun 30, 2021
$2.33M
Aug 4, 2022
Q1
2022
Mar 31, 2021
$2.11M
May 5, 2022
Q3
2021
Sep 30, 2020
$1.52M
Nov 4, 2021
Q2
2021
Jun 30, 2020
$1.51M
Aug 5, 2021
Q1
2021
Mar 31, 2020
$1.49M
May 5, 2021
Q3
2020
Sep 30, 2019
$3.06M
Nov 5, 2020
Q2
2020
Jun 30, 2019
$653.0K
Aug 7, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.74M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
$2.52M
Aug 6, 2025
Q3
2025
Jun 30, 2025
$2.52M
Nov 13, 2025
Q2
2025
Mar 31, 2025
($24.53M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($24.53M)
Nov 13, 2025
Q1
2025
Mar 31, 2025
($24.53M)
May 14, 2025
Q3
2025
Sep 30, 2024
($19.72M)
Nov 13, 2025
Q3
2025
Jun 30, 2024
($19.80M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($19.80M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($17.88M)
Nov 13, 2025
Q2
2025
Mar 31, 2024
($17.88M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($17.88M)
May 14, 2025
Q3
2024
Sep 30, 2023
($20.10M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($17.09M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($17.09M)
Nov 6, 2024
Q3
2024
Mar 31, 2023
($16.34M)
Nov 6, 2024
Q1
2024
Mar 31, 2023
($16.34M)
May 2, 2024
Q2
2024
Mar 31, 2023
($16.34M)
Aug 8, 2024
Q3
2023
Sep 30, 2022
($17.57M)
Nov 7, 2023
Q3
2023
Jun 30, 2022
($14.19M)
Nov 7, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($8.66M)
Nov 13, 2025
Q2
2025
Jun 30, 2025
$1.49M
Aug 6, 2025
Q1
2025
Mar 31, 2025
($25.70M)
May 14, 2025
Q3
2025
Sep 30, 2024
($21.44M)
Nov 13, 2025
Q2
2025
Jun 30, 2024
($21.58M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($19.36M)
May 14, 2025
Q3
2024
Sep 30, 2023
($21.56M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($18.39M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($17.41M)
May 2, 2024
Q3
2023
Sep 30, 2022
($17.81M)
Nov 7, 2023
Q2
2023
Jun 30, 2022
($14.11M)
Aug 3, 2023
Q1
2023
Mar 31, 2022
($10.97M)
May 4, 2023
Q3
2022
Sep 30, 2021
($18.41M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($18.64M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($15.68M)
May 5, 2022
Q3
2021
Sep 30, 2020
($15.22M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($13.14M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($13.15M)
May 5, 2021
Q3
2020
Sep 30, 2019
($91.03M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($20.65M)
Aug 7, 2020